FEDERAL COURT OF AUSTRALIA
Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No 2) [2025] FCA 1082
File number(s): NSD 698 of 2024 Judgment of: JACKMAN J Date of judgment: 2 September 2025 Catchwords: PRACTICE AND PROCEDURE – application to dispense with compliance with notice to produce – concept of relevance applicable to subpoenas also applicable to notices to produce – where documents sought unlikely to relate to issue in proceeding – compliance with notice to produce dispensed with Cases cited: Seven Network (Operations) Ltd v Fairfax Media Publication Pty Ltd [2023] FCAFC 185; (2023) 418 ALR 284
Division: General Division Registry: New South Wales National Practice Area: Intellectual Property Sub-area: Patents and Associated Statutes Number of paragraphs: 8 Date of hearing: 2 September 2025 Counsel for the Applicant: Mr A Ryan SC with Ms S Yates Solicitors for the Applicant: Bird & Bird Counsel for the Respondent: Mr N Murray SC with Mr J Elks Solicitors for the Respondent: Ashurst
ORDERS
NSD 698 of 2024 BETWEEN: ABBEY LABORATORIES PTY LTD
(ACN 156 000 430)Applicant
AND: VIRBAC (AUSTRALIA) PTY LTD
(ACN 003 268 871)Respondent
ORDER MADE BY:
JACKMAN J
DATE OF ORDER:
2 SEPTEMBER 2025
THE COURT ORDERS THAT:
1.Compliance with the notice to produce dated 21 August 2025 be dispensed with.
2.Virbac pay Abbey's costs of the interlocutory application dated 27 August 2025.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
Delivered ex tempore, revised from transcriptJACKMAN J:
In these proceedings, the applicant (Abbey) seeks revocation of Australian Patent Number 2012227241 (the Patent) held by the respondent (Virbac) on the grounds of novelty and lack of inventive step. The Patent concerns formulations for the topical treatment of cattle for parasites. The priority date is 23 September 2011.
Abbey has filed six expert reports by Dr Fadil Alawi, a veterinary pharmaceutical formulator. The first of them is dated 21 August 2024 and was served on 15 October 2024. Dr Alawi details his practical experience in developing pharmaceutical formulations in the animal health industry. Since 2019, Dr Alawi has provided consulting services to animal health companies in relation to new product development and technology transfer through a company, Pharminnovation Ltd. In his first affidavit of 21 August 2024, Dr Alawi explains that in his role as a private consultant and trainer at Pharminnovation Ltd, he provides consulting services, including the development of formulations for new products and the reformulation of existing products, depending on his client's key objectives, This formulation work includes reviewing the results of literature and patent searches, conducting preliminary solubility studies, formulating prototypes that may meet the client's objectives and advising on stability trials. In paragraph [18] of his affidavit, Dr Alawi says the following:
Since April 2019, Pharminnovation Ltd has been retained by Abbey to consult on approximately…
Keep reading for free
Create a free CaseChat account to read Abbey Laboratories Pty Ltd v Virbac (Australia) Pty Ltd (No... and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2025] FCA 1082
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
1. Compliance with the notice to produce dated 21 August 2025 be dispensed with.
2. Virbac pay Abbey's costs of the interlocutory application dated 27 August 2025.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi